search
Back to results

The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response

Primary Purpose

Type 2 Diabetes, Obesity, Pre Diabetes

Status
Completed
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Glucose Solution 1
Glucose Solution 2
Glucose Solution 3
Sucrose/Isomaltulose 100:0
Sucrose/Isomaltulose 0:100
Sucrose/Isomaltulose 50:50
Sucrose/Isomaltulose 60:40
Sucrose/Isomaltulose 70:30
Sucrose/Isomaltulose 80:20
Sponsored by
Clinical Nutrition Research Centre, Singapore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 2 Diabetes

Eligibility Criteria

21 Years - 60 Years (Adult)MaleAccepts Healthy Volunteers
  • Males
  • Asian selected from the three ethnicities Malay, Indian and Chinese
  • Age between 21-60 years
  • Do not partake in sports at the competitive and/or endurance levels
  • Body mass index between 22 to 27 kg/m2
  • Normal blood pressure (<140/80 mmHg)
  • Fasting blood glucose <6 mmol/L
  • Do not have an ongoing infection or currently undergoing treatment at the time of screening
  • Do not have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
  • Do not have active Tuberculosis (TB) or currently receiving treatment for TB
  • Not on any concurrent research study/trials
  • Do not smoke
  • Do not have any metabolic diseases (such as diabetes, hypertension etc)
  • Do not have glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
  • Not having medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics)
  • Do not have intolerances or allergies to foods including the test foods and fructose
  • Do not partake in sports at the competitive and/or endurance levels
  • Do not intentionally restrict food intake
  • Do not have an ongoing infection or currently undergoing treatment at the time of screening
  • Do not have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
  • Do not have active Tuberculosis (TB) or currently receiving treatment for TB
  • Not on any concurrent research study/trials • Do not smoke• Do not have any metabolic diseases (such as diabetes, hypertension etc)
  • Do not have glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
  • Not having medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics)• Do not have intolerances or allergies to foods including the test foods and fructose
  • Do not partake in sports at the competitive and/or endurance levels
  • Do not intentionally restrict food intake
  • Not a team member of the study or is an immediate family member (Immediate family defined as a spouse, parent, child, or sibling, whether biological or legally adopted)

Sites / Locations

  • Clinical Nutrition Research Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Other

Other

Other

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Control 1

Control 2

Control 3

Sucrose/Isomaltulose 100:0

Sucrose/Isomaltulose 0:100

Sucrose/Isomaltulose 50:50

Sucrose/Isomaltulose 60:40

Sucrose/Isomaltulose 70:30

Sucrose/Isomaltulose 80:20

Arm Description

Glucose 50g

Glucose 50g

Glucose 50g

A drink with 50g sucrose/isomaltulose 100:0

A drink with 50g sucrose/isomaltulose 0:100

A drink with 50g sucrose/isomaltulose 50:50

A drink with 50g sucrose/isomaltulose 60:40

A drink with 50g sucrose/isomaltulose 70:30

A drink with 50g sucrose/isomaltulose 80:20

Outcomes

Primary Outcome Measures

Change in postprandial blood glucose over 180 minutes period
Blood obtained through fingerprick, analysed using Hemocue analyser.

Secondary Outcome Measures

Change in postprandial plasma insulin over 180 minutes period
Capillary plasma obtained through finger prick, analysed using Cobas analyser

Full Information

First Posted
November 27, 2020
Last Updated
December 22, 2021
Sponsor
Clinical Nutrition Research Centre, Singapore
search

1. Study Identification

Unique Protocol Identification Number
NCT04653207
Brief Title
The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response
Official Title
The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
October 28, 2020 (Actual)
Study Completion Date
October 28, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Clinical Nutrition Research Centre, Singapore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will determine the glycaemic and insulinaemic response and sensory profile of the drinks with various ratios sucrose:isomaltulose. The information will be useful for manufacturers of beverages to produce blood glucose friendlier drinks. The information will also be useful for dieticians and clinicians in recommending foods and drinks for people with diabetes. The information will also be useful to the public for making better food choices. The data will also provide insights on how the different ratios of sweeteners may affect glycaemic and insulinaemic indices (GI and II).
Detailed Description
The aim of the study is to determine the optimal mixture of sucrose with isomaltulose that will produce optimal reduction in glycaemia and an acceptable sensory profile. These will be assessed among three different ethnicities.The study will recruit a maximum of 60 healthy young (21-60 years old) males from three ethnicities (Malay, Indian, and Chinese). Each participant will take part in 9 separate test sessions on nonconsecutive days, and consume 3 reference control drinks and 6 different test drinks. On each of the test days, participants will consume either the reference drink (50g of anhydrous glucose dissolved in 300 ml of water) or one of the test drinks which consists of 50g of sucrose and/or isomaltulose dissolved in 300 ml of water in the following ratios: 0:100, 100:0, 50:50, 80:20, 70:30, 60:40 sucrose:isomaltulose. Study population: The study will recruit a maximum of 65 healthy young (21-60 years old) males. At least 10 participants will be selected from the three ethnicities (Malay, Indian, and Chinese). Males will be selected in order to avoid effects of the menstrual cycle. Participants will be recruited from the general public in Singapore and will be between 21 and 60 years, with a body mass index between 22 and 27 kg/m2.Design: The experimental protocol adopted is a pre-validated method used repeatedly for measuring the GI of foods. The testing follows a randomised, single-blinded, between-subjects, crossover design with participants returning on 9 non-consecutive days. Reference food testing (standard glucose solution) will precede test food testing. On each test day, participant will consume either the reference drink or one of the test drinks. The test sessions will be made up of 3 identical reference drinks and 6 test drinks. The number sessions each participant will complete will be determined by the researcher and communicated to the participant. For the 9 test sessions, participants arrive at the laboratory between 8:30-9 am following a 10 hour overnight fast. They are instructed not to partake in intense level sports and avoid alcohol consumption on the evening prior to a test session. Following a 10 minute rest two blood samples are obtained five minutes apart for determining baseline blood glucose levels. They are then given either the standard or test drink to consume. They are instructed to consume the food at a comfortable pace within 12 minutes. After consumption of the test drink, subjects will complete a liking questionnaire. Further blood samples are obtained at 15, 30, 45, 60, 90, 120, 150 and 180 minutes for blood glucose measurements and insulin (at every half hour intervals).Reference/Test foods: The reference drink will be anhydrous glucose (50 g) (standard) dissolved in 300 ml of water) and will be consumed on 3 occasions. The test drinks will consist of 50g of sucrose and/or isomaltulose dissolved in 300 ml of water in the following ratios: 0:100, 100:0, 50:50, 80:20, 70:30, 60:40 sucrose:isomaltulose. A total of 6 test drinks will be tested. The participant will be requested to finish both reference and test drink within 12min.Blood collection: Participants will be asked to attend the testing sessions after an overnight fast of ten to twelve hours. Two fasting blood samples will be collected by finger prick for glucose measurement and not more than 0.5ml finger prick blood sample will also be collected to measure baseline insulin. A drop of blood will be collected into a HemoCue® cuvette (Helsingborg, Sweden) for blood glucose analysis. In addition, not more than 0.5ml of finger prick blood will be collected for the analyses of plasma insulin concentrations. Participants will then consume the test meal within 12 minutes. Following this, approximately 5µl of blood samples will be collected at 15, 30, 45, 60, 90, 120, 150 and 180min for glucose measurements and not more than 0.5ml of blood samples will be collected at 30, 60, 90, 120, 150 and 180min for insulin measurements.'Liking' questionnaire: On the testing session days, participants will be asked to rate their 'liking' for the test meal. Participants will be rate their 'overall liking' for the test meal on a 100 mm Visual Analog Scale anchored with 'dislike extremely' (0 mm), 'neither like nor dislike' (50 mm) and 'like extremely' (100 mm) immediately after they consume the test meal.Screening: Potential participants will first attend a screening session for consenting and eligibility procedures. Participants will arrive in the morning following an overnight fast. During the screening, a questionnaire will have to be completed and anthropometry and blood pressure will be assessed. Screening questionnaire: The screening questionnaire will include contact information, demographic, general health details, and physical activity level. This information will be used to determine whether the participant is eligible for the study, as well as to check for any possible confounders that may influence the study outcomes. Anthropometric measurements: Body weight and body composition will be measured using bioelectrical impedance analysis. Height will be measured using a stadiometer in order to calculate participants' BMI. Waist circumference will be measured at the minimum circumference between the iliac crest and the rib cage. Hip circumference will be measured at the maximum protuberance of the buttocks. Blood pressure will also be measured. Blood pressure: Blood pressure will be measured using an Omron blood pressure monitor (Model HEM-907) at baseline. Participants will be seated for five minutes before blood pressure is measured. Measurements will be taken in duplicate and the averaged results will be recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Obesity, Pre Diabetes

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomized crossover study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control 1
Arm Type
Other
Arm Description
Glucose 50g
Arm Title
Control 2
Arm Type
Other
Arm Description
Glucose 50g
Arm Title
Control 3
Arm Type
Other
Arm Description
Glucose 50g
Arm Title
Sucrose/Isomaltulose 100:0
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 100:0
Arm Title
Sucrose/Isomaltulose 0:100
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 0:100
Arm Title
Sucrose/Isomaltulose 50:50
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 50:50
Arm Title
Sucrose/Isomaltulose 60:40
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 60:40
Arm Title
Sucrose/Isomaltulose 70:30
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 70:30
Arm Title
Sucrose/Isomaltulose 80:20
Arm Type
Experimental
Arm Description
A drink with 50g sucrose/isomaltulose 80:20
Intervention Type
Other
Intervention Name(s)
Glucose Solution 1
Intervention Description
50g glucose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Glucose Solution 2
Intervention Description
50g glucose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Glucose Solution 3
Intervention Description
50g glucose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 100:0
Intervention Description
50g sucrose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 0:100
Intervention Description
50g isomaltulose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 50:50
Intervention Description
25g sucrose and 25g isomaltulose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 60:40
Intervention Description
30g sucrose and 20g isomaltulose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 70:30
Intervention Description
35g sucrose and 15g isomaltulose dissolve in 300ml of water
Intervention Type
Other
Intervention Name(s)
Sucrose/Isomaltulose 80:20
Intervention Description
40g sucrose and 10g isomaltulose dissolve in 300ml of water
Primary Outcome Measure Information:
Title
Change in postprandial blood glucose over 180 minutes period
Description
Blood obtained through fingerprick, analysed using Hemocue analyser.
Time Frame
180 minutes
Secondary Outcome Measure Information:
Title
Change in postprandial plasma insulin over 180 minutes period
Description
Capillary plasma obtained through finger prick, analysed using Cobas analyser
Time Frame
180 minutes

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
All healthy male participants
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Males Asian selected from the three ethnicities Malay, Indian and Chinese Age between 21-60 years Do not partake in sports at the competitive and/or endurance levels Body mass index between 22 to 27 kg/m2 Normal blood pressure (<140/80 mmHg) Fasting blood glucose <6 mmol/L Do not have an ongoing infection or currently undergoing treatment at the time of screening Do not have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) Do not have active Tuberculosis (TB) or currently receiving treatment for TB Not on any concurrent research study/trials Do not smoke Do not have any metabolic diseases (such as diabetes, hypertension etc) Do not have glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) Not having medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics) Do not have intolerances or allergies to foods including the test foods and fructose Do not partake in sports at the competitive and/or endurance levels Do not intentionally restrict food intake Do not have an ongoing infection or currently undergoing treatment at the time of screening Do not have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) Do not have active Tuberculosis (TB) or currently receiving treatment for TB Not on any concurrent research study/trials • Do not smoke• Do not have any metabolic diseases (such as diabetes, hypertension etc) Do not have glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) Not having medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics)• Do not have intolerances or allergies to foods including the test foods and fructose Do not partake in sports at the competitive and/or endurance levels Do not intentionally restrict food intake Not a team member of the study or is an immediate family member (Immediate family defined as a spouse, parent, child, or sibling, whether biological or legally adopted)
Facility Information:
Facility Name
Clinical Nutrition Research Centre
City
Singapore
ZIP/Postal Code
117599
Country
Singapore

12. IPD Sharing Statement

Learn more about this trial

The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response

We'll reach out to this number within 24 hrs